GURUFOCUS.COM » STOCK LIST » Oceania » Australia » ASX » Prescient Therapeutics Ltd (ASX:PTX) » Definitions » 1-Year ROIIC %
Switch to:

Prescient Therapeutics (ASX:PTX) 1-Year ROIIC %

: -1,791.14% (As of Dec. 2022)
View and export this data going back to 1986. Start your Free Trial

1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year. Prescient Therapeutics's 1-Year ROIIC % for the quarter that ended in Dec. 2022 was -1,791.14%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Prescient Therapeutics's 1-Year ROIIC % or its related term are showing as below:

ASX:PTX's 1-Year ROIIC % is ranked worse than
93.36% of 1446 companies
in the Biotechnology industry
Industry Median: -9.11 vs ASX:PTX: -1791.14

Competitive Comparison

For the Biotechnology subindustry, Prescient Therapeutics's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prescient Therapeutics 1-Year ROIIC % Distribution

For the Biotechnology industry and Healthcare sector, Prescient Therapeutics's 1-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Prescient Therapeutics's 1-Year ROIIC % falls in comparison to its industry or sector. The grey bar indicates the 1-Year ROIIC %'s extreme value range as defined by GuruFocus.

Prescient Therapeutics 1-Year ROIIC % Calculation

Prescient Therapeutics's 1-Year ROIIC % for the quarter that ended in Dec. 2022 is calculated as:

1-Year ROIIC %=1-Year Incremental Net Operating Profit After Taxes (NOPAT)**/1-Year Incremental Invested Capital
=( -7.883 (Dec. 2022) - -6.468 (Dec. 2021) )/( 4.077 (Dec. 2022) - 3.998 (Dec. 2021) )
=-1,791.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

**While calculating 1-Year ROIIC %, twelve months (TTM) data for NOPAT will be applied if latest quarterly financials are available after its last annual reports. Otherwise, annual data will be used.

Prescient Therapeutics  (ASX:PTX) 1-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.

Prescient Therapeutics 1-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Prescient Therapeutics's 1-Year ROIIC % provided by Please click on the following links to see related term pages.

Prescient Therapeutics (ASX:PTX) Business Description

Prescient Therapeutics logo
Traded in Other Exchanges
Level 4, 100 Albert Road, South Melbourne, Melbourne, VIC, AUS, 3205
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.

Prescient Therapeutics (ASX:PTX) Headlines

No Headlines